Gennex Laboratories Ltd
BSE:531739
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its Industry Average (28), the stock would be worth ₹-91.16 (987% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -3.2 | ₹10.28 |
0%
|
| Industry Average | 28 | ₹-91.16 |
-987%
|
| Country Average | 23.4 | ₹-76.4 |
-843%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Gennex Laboratories Ltd
BSE:531739
|
2.5B INR | -3.2 | 12.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
867B USD | 53.5 | 42 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.4B USD | 23.7 | 26.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 15.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.8B GBP | 21.2 | 28.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 15.3 | 19.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.6B USD | 19.2 | 15.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 936 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 10.5 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.6B USD | 17.1 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.8B USD | 10.7 | 16.8 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 14.7 |
| Median | 23.4 |
| 70th Percentile | 39.6 |
| Max | 28 676 |
Other Multiples
Gennex Laboratories Ltd
Glance View
Gennex Laboratories Ltd. engages in the manufacture of bulk drugs and intermediates products. The company is headquartered in Hyderabad, Telangana. The firm is engaged in the business of manufacturing of bulk drugs, intermediaries and biotech products. The firm has a robust product portfolio spread over major product segments encompassing expectorants, muscle relaxants, analgesic and anti-fungal. The firm operates through Pharmaceutical Products (Bulk Drugs) segment. The firm's products include active pharmaceutical ingredients, such as Guaifenesin USP/BP/EP/IP, which is an expectorant, (mucolyte); Methocarbamol USP, which is a relaxant (skeletal muscle relaxant); Phenazopyridine Hcl USP, which is an urinary tract analgesic; Fluconazole EP/USP, which is an anti-fungal product; Mephenesin IP/BP, which is a muscle relaxant; Chlorphenesin IP/BP, which is anti-fungal, and Melitracen Hcl, which is an antidepressant. The firm has manufacturing facilities in India which caters to both domestic and international markets.
